BioSpace News Archive

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has completed patient enrollment in its Phase 3 REVERSE study evaluating obeticholic acid (OCA) for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).

InnerScope introduces a Dietary Hearing Supplement that supports both the Brain & Hearing Health for Americans age 50 and older who are buying the biggest slice of the very large brain-health dietary supplements market, which is expected to reach $5.8 billion in sales by 2023

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s lead product candidate, DSG3-CAART, for the treatment of pemphigus vulgaris (PV)

VADovations, Inc., a company developing miniaturized cardiac assist pumps offering best-in-class blood handling properties, high performance and low cost, today announces an agreement to license intellectual property from Mayo Clinic for endovascular deployment of VADovations’ novel cardiac assist pump for long-term use in patients suffering with heart failure.

Polarean Imaging plc (AIM: POLX), a clinical stage medical imaging technology company developing a proprietary magnetic resonance imaging (MRI) drug-device combination, today announced positive top-line results from two pivotal Phase III clinical trials of the Company’s drug-device combination, which uses hyperpolarized 129Xenon gas MRI to visualize and quantify regional lung function.

Biodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.

Winner from month-long contest honoring unsung heroes will receive a special care package from the award-winning actress

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the use of any anti-PVRIG antibody in the treatment of cancer.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 26, at 4:30 p.m. ET to discuss fourth quarter and full year 2019 financial results and provide a general business update.

Current Health will offer its RPM device to C-section patients at Ugandan hospital to improve inpatient monitoring